Kim Yeiseok
Transaction: 03/26/2026
OTHER
Change
0
Price
Not reported
Filing
04/16/2026
Type
OTHER
OSR Holdings, Inc.
OSRH • Biotechnology
Extraordinary move
OSRH+43.78%
vs. previous close $0.12
$0.17
▲ +0.05 (+43.78%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$750,735
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.06Weak liquidity · 0.16Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:18 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.17
Change43.78%
Shares Out4.48M
Market Cap$750.74K
Enterprise Value$-170.68K
52W Range0.25 - 1.24
Beta0.58
P/E-0.05
P/S0.42
P/B0.01
P/FCF-0.10
EV/Sales-0.09
Price$0.17
Change43.78%
Shares Out4.48M
Market Cap$750.74K
Enterprise Value$-170.68K
52W Range0.25 - 1.24
Beta0.58
P/E-0.05
P/S0.42
P/B0.01
P/FCF-0.10
EV/Sales-0.09
EV/EBITDA0.01
EV/FCF0.02
FCF Yield-959.57%
Dividend Yield0.00%
Gross Margin20.40%
Oper. Margin-6.31%
Profit Margin-6.20%
Debt/Eq0.06
Current Ratio0.16
Quick Ratio0.15
Volume2.67M
Avg Volume6.15M
EPS Surprise0.20
Investment DNA
How strong this company looks for long-term investors
38
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
39/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.06Weak liquidity · 0.16Negative growth trendWeak profitability
Analyst view
No analyst data available now.
Insider Transactions
Recent executive and insider activity
Fierz Reto Kaspar
Transaction: 09/17/2025
OTHER
Change
0
Price
Not reported
Filing
10/24/2025
Type
OTHER
Kim Sang Harry
Transaction: 02/14/2025
OTHER
Change
0
Price
Not reported
Filing
02/21/2025
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Kim Yeiseok | OTHER | 0 | Not reported | 03/26/2026 | 04/16/2026 |
| Fierz Reto Kaspar | OTHER | 0 | Not reported | 09/17/2025 | 10/24/2025 |
| Kim Sang Harry | OTHER | 0 | Not reported | 02/14/2025 | 02/21/2025 |
| Barberis Alcide | OTHER | 0 | Not reported | 02/14/2025 | 02/21/2025 |
| Cho Joong Myung | OTHER | 0 | Not reported | 02/14/2025 | 02/21/2025 |
| Jee Hyuk Joo | OTHER | 0 | Not reported | 02/14/2025 | 02/20/2025 |
| Bang Gihyoun | OTHER | 0 | Not reported | 02/14/2025 | 02/20/2025 |
| BCM Europe AG | OTHER | 0 | Not reported | 02/14/2025 | 02/19/2025 |
| Bellevue Capital Management LLC | OTHER | 0 | Not reported | 02/14/2025 | 02/19/2025 |
| Hwang Kuk Hyoun | BUY | +43,000 | Not reported | 02/14/2025 | 02/19/2025 |
| Bellevue Global Life Science Investors LLC | BUY | +43,000 | Not reported | 02/14/2025 | 02/19/2025 |
| Kim Sang Hyun | OTHER | 0 | Not reported | 06/23/2024 | 07/02/2024 |
| Lee Phil Geon | OTHER | 0 | Not reported | 05/27/2024 | 06/04/2024 |
| Bellevue Global Life Science Investors LLC | SELL | -20,000 | $11.50 | 03/23/2023 | 03/27/2023 |
| Bellevue Global Life Science Investors LLC | SELL | -20,000 | Not reported | 03/23/2023 | 03/27/2023 |
| Yoo David Jin | BUY | +20,000 | $11.50 | 03/23/2023 | 03/27/2023 |
| Yoo David Jin | BUY | +20,000 | Not reported | 03/23/2023 | 03/27/2023 |
| Hwang Kuk Hyoun | SELL | -20,000 | $11.50 | 03/23/2023 | 03/27/2023 |
| Hwang Kuk Hyoun | SELL | -20,000 | Not reported | 03/23/2023 | 03/27/2023 |
| Bellevue Global Life Science Investors LLC | SELL | -4,500 | Not reported | 02/21/2023 | 02/23/2023 |